Hepatic Failure Pathology
Acute liver failure (ALF) is defined as severe hepatic dysfunction with coagulopathy (INR ≥1.5) and encephalopathy in a patient without pre-existing liver disease, developing within 26 weeks of symptom onset....
Clinical board
A visual summary of the highest-yield teaching signals on this page.
Urgent signals
Safety-critical features pulled from the topic metadata.
- INR >6.5 in paracetamol ALF indicates severe hepatocyte loss
- Grade III-IV encephalopathy with cerebral oedema risk - requires ICP monitoring
- Lactate >3.5 mmol/L after resuscitation predicts poor prognosis
- Arterial ammonia >150 μmol/L associated with cerebral herniation risk
Exam focus
Current exam surfaces linked to this topic.
- CICM First Part Written SAQ
- CICM First Part Written MCQ
- CICM First Part Viva
Editorial and exam context
Hepatic Failure Pathology
Quick Answer
Acute liver failure (ALF) is defined as severe hepatic dysfunction with coagulopathy (INR ≥1.5) and encephalopathy in a patient without pre-existing liver disease, developing within 26 weeks of symptom onset. Classification by timing: hyperacute (<7 days), acute (7-21 days), subacute (21 days - 26 weeks). Paracetamol toxicity is the leading cause in Australia (50-60%), causing centrilobular (Zone 3) hepatocyte necrosis via NAPQI-mediated glutathione depletion and oxidative stress. Multi-organ dysfunction includes coagulopathy (reduced synthesis of factors II, VII, IX, X but ALSO anticoagulants - creating "rebalanced haemostasis"), hepatic encephalopathy (ammonia → glutamine → astrocyte swelling), cerebral oedema (cytotoxic mechanism with herniation risk), hyperdynamic circulation (low SVR), hepatorenal syndrome (Type 1 - rapidly progressive), and immune dysfunction (SIRS response with infection susceptibility). King's College Criteria guide transplant listing.
CICM Exam Focus
SAQ Topics (First Part Written)
- Define acute liver failure and classify by temporal onset pattern
- Describe the mechanism of paracetamol hepatotoxicity including NAPQI formation and zonality
- Explain the pathophysiology of hepatic encephalopathy including ammonia metabolism
- Describe the coagulation abnormalities in ALF and the concept of "rebalanced haemostasis"
- Explain the mechanisms of cerebral oedema in acute liver failure
- Describe the pathophysiology of hepatorenal syndrome
Viva Topics
- Hepatocyte death pathways: necrosis vs apoptosis in ALF
- Metabolic derangements in ALF (hypoglycaemia, lactate, electrolytes)
- Haemodynamic changes in liver failure: hyperdynamic circulation
- Immune dysfunction and SIRS in ALF
- Prognostic scoring: King's College Criteria and MELD
- Hepatic regeneration mechanisms
Common Examiner Questions
- "Explain why Zone 3 is preferentially affected in paracetamol toxicity"
- "Why might bleeding be less of a problem than expected in ALF despite high INR?"
- "Describe the pathophysiology linking hyperammonaemia to cerebral oedema"
- "What are the mechanisms of renal failure in hepatorenal syndrome?"
- "How does ALF cause immune dysfunction and increase infection risk?"
Key Points
Acute liver failure (ALF) requires: (1) Coagulopathy (INR ≥1.5), (2) Hepatic encephalopathy, (3) No pre-existing cirrhosis, (4) Illness duration <26 weeks. O'Grady classification: Hyperacute (<7 days - best prognosis), Acute (7-21 days), Subacute (21 days - 26 weeks - worst prognosis with transplant-free survival).
CYP2E1/CYP1A2 convert paracetamol to NAPQI (N-acetyl-p-benzoquinone imine). NAPQI is normally conjugated by glutathione. In overdose, glutathione depletion allows NAPQI to bind covalently to cellular proteins, causing mitochondrial dysfunction, oxidative stress, and hepatocyte death predominantly in Zone 3 (centrilobular) due to highest CYP2E1 concentration.
Zone 3 (centrilobular, perivenular) is most susceptible to paracetamol, hypoxia, and many toxins due to: lowest oxygen tension, highest CYP450 concentration, lowest glutathione levels. Zone 1 (periportal) is preferentially damaged by phosphorus poisoning and some viral hepatitides. Bridging necrosis connects portal and central areas.
ALF reduces synthesis of BOTH procoagulant factors (II, VII, IX, X, fibrinogen) AND anticoagulants (Protein C, Protein S, Antithrombin). The INR only measures procoagulants. In practice, haemostasis is often "rebalanced"
- patients may not bleed excessively despite markedly elevated INR. However, the balance is precarious and can tip toward thrombosis or haemorrhage.
Ammonia (from gut bacteria, GI bleeding, renal production) accumulates due to impaired hepatic conversion to urea. In astrocytes, ammonia combines with glutamate to form glutamine (via glutamine synthetase), which is osmotically active, causing astrocyte swelling. Additional mechanisms: neuroinflammation, GABA-ergic tone, false neurotransmitters, manganese accumulation.
Unlike chronic liver disease, ALF causes significant cerebral oedema primarily through CYTOTOXIC mechanism (astrocyte swelling from glutamine accumulation). The blood-brain barrier remains largely intact. Ammonia >150 μmol/L and Grade III-IV encephalopathy are major risk factors. Cerebral oedema can cause intracranial hypertension and herniation (20-25% of ALF deaths).
HRS represents functional renal failure due to: (1) Splanchnic vasodilation (NO, prostacyclin) causing relative hypovolemia, (2) Compensatory RAAS and SNS activation causing renal vasoconstriction, (3) Reduced effective circulating volume. Type 1 HRS: rapidly progressive (creatinine doubles in <2 weeks); Type 2: slowly progressive (associated with refractory ascites).
ALF causes systemic vasodilation (reduced SVR to 800-1200 dyn·s/cm⁵) with compensatory increased cardiac output (hyperdynamic state). Mechanisms: increased NO production (iNOS upregulation), prostaglandins, endotoxemia from gut translocation. Similar to sepsis physiology. Portal hypertension develops acutely due to hepatic sinusoidal disruption.
ALF causes paradoxical immune dysfunction despite SIRS response: reduced complement, impaired Kupffer cell function, decreased opsonisation, neutrophil dysfunction. SIRS criteria met in 50-60% of ALF. Infection occurs in 50-80% of patients. Common organisms: Staphylococcus, Streptococcus, enteric Gram-negatives, Candida.
For paracetamol ALF: pH <7.30 after resuscitation OR (INR >6.5 AND creatinine >300 μmol/L AND Grade III-IV encephalopathy). For non-paracetamol ALF: INR >6.5 OR any 3 of: age <10 or >40, non-A non-B hepatitis/drug reaction, jaundice >7 days before encephalopathy, INR >3.5, bilirubin >300 μmol/L. Positive predictive value ~90% for transplant requirement.
Definition and Classification
Acute Liver Failure: Definition
Acute liver failure (ALF) is defined by the presence of (PMID: 21757548):
Essential Features:
- Coagulopathy: INR ≥1.5 (or PT ≥15 seconds)
- Hepatic encephalopathy: Any grade (I-IV)
- No pre-existing chronic liver disease: Exceptions - acute Wilson's disease, reactivation of hepatitis B, autoimmune hepatitis flare
- Illness duration: <26 weeks from onset of symptoms
Key Distinction: Acute-on-chronic liver failure (ACLF) describes decompensation of pre-existing cirrhosis and has different pathophysiology and management.
Temporal Classification (O'Grady Classification)
The O'Grady classification (1993) stratifies ALF by jaundice-to-encephalopathy interval (PMID: 8242296):
| Classification | Jaundice to Encephalopathy | Typical Causes | Cerebral Oedema Risk | Transplant-Free Survival |
|---|---|---|---|---|
| Hyperacute | <7 days | Paracetamol, hepatitis A/B, ischaemic | HIGH (↑↑) | Best (36-55%) |
| Acute | 7-21 days | Hepatitis B, drug reactions | Moderate (↑) | Intermediate (7-15%) |
| Subacute | 21 days - 26 weeks | Drug reactions, seronegative hepatitis | Lower (↓) | Worst (7-14%) |
Hyperacute liver failure (especially paracetamol) has the HIGHEST cerebral oedema risk but the BEST transplant-free survival if the patient survives the acute phase. This reflects the liver's remarkable regenerative capacity following a single massive insult. Subacute failure has ongoing hepatocyte destruction outpacing regeneration, leading to poorer outcomes.
Alternative Classification: AASLD/ALFSG
The US Acute Liver Failure Study Group uses slightly different terminology (PMID: 21757548):
| Category | Jaundice to Encephalopathy |
|---|---|
| Acute liver failure | <26 weeks |
| Fulminant hepatic failure | <8 weeks |
| Subfulminant hepatic failure | 8-26 weeks |
Aetiology of Acute Liver Failure
Overview of Causes
Australia/New Zealand:
- Paracetamol: 50-60% (leading cause)
- Drug-induced (non-paracetamol): 10-15%
- Viral hepatitis: 10-15%
- Indeterminate: 10-15%
- Other: 5-10%
Developing World:
- Viral hepatitis (A, B, E): 40-50%
- Indeterminate: 20-30%
- Drug-induced: 10-15%
Paracetamol (Acetaminophen) Hepatotoxicity
Paracetamol is the most common cause of ALF in Australia, UK, and USA (PMID: 18768945).
Single Acute Overdose vs Staggered Overdose
| Pattern | Definition | NAC Protocol | Prognosis |
|---|---|---|---|
| Single acute ingestion | All tablets within 1 hour | Rumack-Matthew nomogram applicable | Generally better |
| Staggered overdose | Multiple supra-therapeutic doses over >1 hour | Nomogram NOT applicable; treat based on clinical findings | Often worse - delayed presentation |
Risk Factors for Hepatotoxicity
Patient Factors (reduced glutathione):
- Chronic alcohol use (CYP2E1 induction, glutathione depletion)
- Malnutrition, fasting (depleted glycogen and glutathione)
- Enzyme-inducing medications (phenytoin, carbamazepine, rifampicin)
- Chronic liver disease
Dose Factors:
- Acute ingestion >150 mg/kg (adults) or >200 mg/kg (children) concerning
-
7.5 g in adults considered potentially hepatotoxic
- Therapeutic misadventure often involves multiple products containing paracetamol
Viral Hepatitis
| Virus | ALF Frequency | Epidemiology | Special Features |
|---|---|---|---|
| Hepatitis A | <1% of HAV infections | Faecal-oral; outbreaks in Indigenous communities | Higher ALF risk in underlying liver disease |
| Hepatitis B | 1-4% of acute HBV | Parenteral/sexual; higher rates in Indigenous populations | Reactivation in immunosuppression can cause ALF |
| Hepatitis D | Co-infection or superinfection | Parenteral; requires HBV | High mortality with superinfection |
| Hepatitis E | Up to 25% in pregnancy | Faecal-oral; waterborne; travel-associated | Major cause in endemic areas; dangerous in pregnancy |
Immunosuppression (chemotherapy, rituximab, TNF-α inhibitors, transplantation) can cause HBV reactivation in patients with past infection (HBsAg-negative, anti-HBc positive). Fulminant hepatic failure may occur. All patients should be screened for HBV before immunosuppressive therapy.
Drug-Induced Liver Injury (DILI)
Common culprits in Australia (PMID: 20937949):
| Drug/Class | Pattern | Mechanism | Comments |
|---|---|---|---|
| Anti-tuberculosis (INH, Rifampicin, Pyrazinamide) | Hepatocellular or mixed | Metabolic, immunoallergic | Combination increases risk |
| Antibiotics (Amoxicillin-clavulanate) | Cholestatic or mixed | Immunoallergic | Most common DILI cause overall |
| NSAIDs | Hepatocellular | Metabolic | Diclofenac, sulindac higher risk |
| Anticonvulsants (Phenytoin, valproate) | Hepatocellular | Metabolic | Valproate: mitochondrial toxicity |
| Statins | Hepatocellular | Idiosyncratic | Rare, usually reversible |
| Herbal/supplements | Variable | Variable | Often unrecognised; kava, black cohosh, comfrey |
Wilson's Disease
An important cause of ALF in young patients (<40 years) (PMID: 18506894):
- Pathophysiology: ATP7B gene mutation → copper accumulation → oxidative damage, mitochondrial dysfunction
- Key features: Kayser-Fleischer rings (95% in neurological Wilson's), Coombs-negative haemolytic anaemia (copper release), low serum ceruloplasmin
- ALF presentation: Often presents with features suggesting haemolysis (low ceruloplasmin, high bilirubin:ALP ratio, Coombs-negative haemolysis)
- Prognostic scoring: Wilson's Disease Prognostic Index (bilirubin, AST, INR, albumin, WCC) - score ≥11 indicates need for transplant
Suspect Wilson's when ALF occurs with:
- ALP:bilirubin ratio <4
- AST:ALT ratio >2.2
- Coombs-negative haemolytic anaemia
- Low serum ceruloplasmin (<0.2 g/L)
- High 24-hour urinary copper (>100 μg)
- Kayser-Fleischer rings on slit-lamp examination
Wilson's ALF requires urgent transplant listing as spontaneous recovery does not occur.
Pregnancy-Related Causes
| Condition | Timing | Features | Delivery Required |
|---|---|---|---|
| Acute fatty liver of pregnancy (AFLP) | 3rd trimester | Hypoglycaemia, DIC, encephalopathy, microvesicular steatosis | Yes - curative |
| HELLP syndrome | 2nd-3rd trimester | Haemolysis, Elevated Liver enzymes, Low Platelets | Yes |
| Hepatic rupture | 3rd trimester, pre-eclampsia | Sudden severe pain, haemodynamic collapse | Surgical emergency |
AFLP Pathophysiology: Often associated with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency in fetus → accumulation of fatty acid metabolites → maternal hepatotoxicity (PMID: 10515901).
Other Causes
| Cause | Key Features |
|---|---|
| Ischaemic (hypoxic) hepatitis | "Shock liver" |
- massive AST/ALT elevation (thousands), rapid resolution if perfusion restored | | Budd-Chiari syndrome | Hepatic vein thrombosis; acute presentation can cause ALF | | Mushroom poisoning (Amanita phalloides) | α-amanitin inhibits RNA polymerase II; delayed GI symptoms → hepatic failure | | Autoimmune hepatitis | May present as ALF; responds to corticosteroids in some cases | | Heat stroke | Massive cytokine release, ischaemia, direct thermal injury | | Malignant infiltration | Lymphoma, metastatic breast cancer - rare cause |
Hepatocyte Death Pathways
Overview
Hepatocyte death in ALF occurs through two major pathways: necrosis and apoptosis. The predominant pathway depends on the aetiology and severity of injury (PMID: 23720129).
Necrosis vs Apoptosis
| Feature | Necrosis | Apoptosis |
|---|---|---|
| Trigger | Severe, overwhelming injury | Controlled signals, moderate injury |
| Energy requirement | ATP-independent | ATP-dependent |
| Morphology | Cell swelling, membrane rupture, karyolysis | Cell shrinkage, chromatin condensation, apoptotic bodies |
| Inflammation | Severe - DAMPs released | Minimal - "clean" death |
| Process | Uncontrolled, passive | Programmed, regulated |
| Key mediators | ROS, calcium overload, ATP depletion | Caspases (3, 7, 8, 9) |
| Dominant in | Paracetamol (severe), ischaemia | Viral hepatitis, DILI (some), Fas-mediated |
Paracetamol-Induced Hepatocyte Death
NAPQI Formation and Toxicity
The mechanism of paracetamol hepatotoxicity is well-characterised (PMID: 23720129, PMID: 25033466):
Step 1: Metabolism
- 90% of paracetamol: glucuronidation (UGT) and sulfation (SULT) → non-toxic metabolites
- 5-10%: CYP450 oxidation (primarily CYP2E1, also CYP1A2, CYP3A4) → NAPQI
Step 2: Detoxification
- NAPQI normally conjugated with glutathione (GSH) → non-toxic mercapturic acid
- Requires adequate glutathione stores
Step 3: Toxicity (in overdose)
- Glutathione depleted (typically >70% depletion)
- Excess NAPQI binds covalently to cellular proteins (especially mitochondrial proteins)
- Protein adducts disrupt mitochondrial respiration
Step 4: Mitochondrial Dysfunction
- Inhibition of electron transport chain
- Decreased ATP production
- Increased reactive oxygen species (ROS) production
- Mitochondrial permeability transition pore (mPTP) opening
Step 5: Cell Death
- ATP depletion → necrosis
- Cytochrome c release → apoptosis (if ATP sufficient)
- Release of endonucleases → nuclear DNA fragmentation
- JNK (c-Jun N-terminal kinase) activation amplifies mitochondrial injury
The Role of JNK (c-Jun N-terminal Kinase)
JNK is a critical amplifier of paracetamol toxicity (PMID: 20673547):
- Initial NAPQI-protein adducts cause mitochondrial dysfunction
- ROS production activates JNK in cytoplasm
- Activated JNK translocates to mitochondria
- JNK amplifies ROS production and inhibits electron transport
- This creates a positive feedback loop of mitochondrial injury
NAC (N-acetylcysteine) is the antidote for paracetamol toxicity because it:
- Replenishes glutathione: Provides cysteine for GSH synthesis (primary mechanism early)
- Acts as antioxidant: Directly scavenges ROS
- Improves mitochondrial function: Supports respiratory chain (mechanism of late benefit)
- Enhances sulfation: Alternative conjugation pathway
NAC is most effective within 8-10 hours but provides benefit even up to 24+ hours post-ingestion through mechanisms beyond GSH repletion.
Zonality of Hepatic Injury
The liver acinus (functional unit) has three zones with different metabolic properties (PMID: 24905494):
| Zone | Location | O₂ Tension | CYP450 Activity | Glutathione | Injury Pattern |
|---|---|---|---|---|---|
| Zone 1 | Periportal | Highest | Lowest | Highest | Phosphorus, iron, some viruses |
| Zone 2 | Intermediate | Moderate | Intermediate | Intermediate | Mixed |
| Zone 3 | Centrilobular (perivenular) | Lowest | Highest (especially CYP2E1) | Lowest | Paracetamol, alcohol, hypoxia, CCl₄ |
Why Zone 3 is Most Susceptible to Paracetamol
- Highest CYP2E1 concentration: More NAPQI generated per hepatocyte
- Lowest oxygen tension: Impairs aerobic metabolism when stressed
- Lowest glutathione: Less capacity to detoxify NAPQI
- Lowest NADPH: Reduced regeneration of glutathione
- Centrifugal blood flow: Toxins accumulate as blood flows centrally
Histopathology of Hepatocyte Death
Necrosis Patterns
| Pattern | Description | Causes |
|---|---|---|
| Centrilobular (Zone 3) necrosis | Death around central vein, sparing portal tracts | Paracetamol, hypoxia, CCl₄ |
| Periportal (Zone 1) necrosis | Death around portal tracts | Phosphorus, eclampsia |
| Bridging necrosis | Necrosis connecting portal-central or portal-portal | Severe viral hepatitis, DILI |
| Massive (panacinar) necrosis | Confluent necrosis of entire acini | Fulminant ALF (any cause) |
| Submassive necrosis | Extensive but not complete necrosis | Severe hepatitis |
Microscopic Features of ALF
- Hepatocyte dropout: Empty spaces where hepatocytes were
- Collapse of reticulin framework: Architecture destroyed
- Inflammatory infiltrate: Lymphocytes, macrophages, neutrophils
- Ductular reaction: Proliferation of biliary epithelium (regenerative response)
- Cholestasis: Bile plugs in canaliculi
- Mallory-Denk bodies: May be seen in alcoholic, NASH, some drug injury
Coagulopathy in Acute Liver Failure
Synthesis Failure
The liver synthesises virtually all coagulation factors (except Factor VIII and von Willebrand factor) (PMID: 26070319):
Pro-coagulant Factors Affected
| Factor | Half-life | Clinical Significance |
|---|---|---|
| Factor VII | 4-6 hours | Shortest half-life; INR rises earliest |
| Factor II (Prothrombin) | 60-72 hours | Major component of PT/INR |
| Factor V | 12-24 hours | Both synthesis and consumption; marker of severity |
| Factor IX | 18-24 hours | Intrinsic pathway |
| Factor X | 40-60 hours | Common pathway |
| Fibrinogen | 3-5 days | May be normal or elevated (acute phase response) early |
Factor V is synthesised ONLY by the liver and is consumed in DIC. Factor V level <20% correlates with very poor prognosis in ALF. It is used in some prognostic models (Clichy criteria) as it reflects both synthetic function and consumption.
The Concept of "Rebalanced Haemostasis"
Traditional teaching suggested ALF patients have severe bleeding risk due to coagulopathy. However, modern understanding recognises a more complex picture (PMID: 26070319, PMID: 20947927):
Procoagulant Deficits:
- Factors II, V, VII, IX, X, XI
- Fibrinogen (variable)
Anticoagulant Deficits (equally or more reduced):
- Protein C (half-life 8 hours) - often profoundly reduced
- Protein S
- Antithrombin
- ADAMTS13 (vWF cleaving protease)
Net Effect:
- INR/PT reflects ONLY procoagulant loss (not anticoagulant loss)
- Thrombin generation may be NORMAL or even INCREASED
- Patients are often at risk of THROMBOSIS as well as bleeding
- The balance is precarious - can tip either way with additional insults
Clinical Implications
- INR does not predict bleeding: Standard INR correlates poorly with bleeding risk in ALF
- Prophylactic FFP not recommended: Unless bleeding or invasive procedure planned
- Thromboelastography (TEG/ROTEM): Better reflects global coagulation status
- VTE prophylaxis: May be appropriate despite elevated INR (assess individually)
- Avoid vitamin K deficiency: Give vitamin K but don't expect full INR correction
Additional Haemostatic Abnormalities
| Abnormality | Mechanism | Clinical Effect |
|---|---|---|
| Thrombocytopenia | Reduced TPO production, splenic sequestration, consumption | Usually moderate (50-100 × 10⁹/L) |
| Platelet dysfunction | Uremia, NO, prostacyclin | Prolonged bleeding time |
| Hyperfibrinolysis | Reduced α2-antiplasmin, reduced PAI-1, increased tPA | May cause bleeding |
| Reduced plasminogen | Synthetic failure | Impaired clot lysis |
| Elevated vWF | Endothelial activation, reduced ADAMTS13 | Pro-thrombotic |
Disseminated Intravascular Coagulation
DIC may complicate ALF (PMID: 31327219):
- Incidence: 20-30% of severe ALF
- Triggers: Tissue factor release from necrotic hepatocytes, endotoxaemia, sepsis
- Features: Thrombocytopenia, elevated D-dimer, microangiopathic haemolysis (rare)
- Management: Treat underlying cause; blood products only for active bleeding
Hepatic Encephalopathy
Definition and Grading
Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction (PMID: 24866571):
| Grade | Clinical Features | Mental Status |
|---|---|---|
| Minimal (Covert) | Abnormal psychometric testing, no clinical signs | Normal on examination |
| Grade I (Covert) | Mild confusion, euphoria or depression, shortened attention span, sleep disturbance | Orientated |
| Grade II (Overt) | Drowsiness, disorientation, inappropriate behaviour, asterixis | Disorientated to time |
| Grade III (Overt) | Marked confusion, incoherent speech, sleepy but rousable, gross disorientation | Disorientated to time and place |
| Grade IV (Overt) | Coma (unrousable to painful stimuli) | Coma |
Pathophysiology of Hepatic Encephalopathy
HE is multifactorial but ammonia is central to the pathophysiology (PMID: 25042402):
Ammonia Metabolism
Normal ammonia handling:
- Sources: Gut bacteria (urease), enterocyte glutaminase, renal ammoniagenesis, muscle deamination
- Absorption: Absorbed from colon into portal circulation
- Hepatic clearance: Periportal hepatocytes convert NH₃ to urea (urea cycle) - 85% of ammonia clearance
- Alternative pathway: Perivenous hepatocytes convert NH₃ to glutamine (glutamine synthetase)
In liver failure:
- Reduced hepatocyte mass → impaired urea cycle capacity
- Porto-systemic shunting → bypasses liver
- Arterial ammonia levels rise (normal <50 μmol/L; HE often >100 μmol/L)
The Ammonia-Glutamine-Astrocyte Swelling Pathway
This is the key mechanism linking hyperammonaemia to cerebral dysfunction (PMID: 25042402):
- Ammonia crosses BBB: NH₃ (un-ionised) freely crosses blood-brain barrier
- Astrocyte uptake: Ammonia enters astrocytes
- Glutamine synthesis: Glutamine synthetase (in astrocytes) converts glutamate + NH₃ → glutamine
- Osmotic effect: Glutamine is osmotically active → astrocyte swelling
- Mitochondrial toxicity: Glutamine enters mitochondria → generates ammonia locally → mitochondrial dysfunction
- Oxidative stress: ROS generation, impaired energy metabolism
Neurons do not express glutamine synthetase. Astrocytes are the only CNS cells capable of ammonia detoxification, making them the primary target of ammonia toxicity. Astrocyte swelling, a form of cytotoxic oedema, is the hallmark of HE in ALF.
Additional Mechanisms in HE
| Mechanism | Contribution |
|---|---|
| GABA-ergic tone | Increased endogenous benzodiazepine-like substances, increased GABA receptor sensitivity |
| Neuroinflammation | Microglial activation, cytokine production (synergises with ammonia) |
| Manganese accumulation | Normally excreted in bile; deposits in basal ganglia (T1 MRI hyperintensity) |
| False neurotransmitters | Aromatic amino acids (phenylalanine, tyrosine) cross BBB; compete with catecholamine synthesis |
| Zinc deficiency | Zinc is cofactor for urea cycle enzymes; deficiency worsens HE |
| Altered tryptophan metabolism | Increased serotonin precursors may contribute to altered consciousness |
Precipitants of Hepatic Encephalopathy
In ALF, HE develops due to acute hepatocyte loss. In cirrhosis, precipitants should be sought:
| Precipitant | Mechanism |
|---|---|
| GI bleeding | Protein load → increased ammonia production |
| Constipation | Prolonged colonic transit → more ammonia absorbed |
| Infection/sepsis | Catabolism, neuroinflammation, reduced cerebral perfusion |
| Electrolyte imbalance | Hypokalaemia and metabolic alkalosis favour NH₃ (crosses BBB) over NH₄⁺ |
| Dehydration | Reduced renal ammonia excretion |
| Sedatives/opioids | Direct CNS depression; mask HE progression |
| Dietary protein excess | Increased ammonia substrate (rare cause) |
| Portosystemic shunt (TIPS) | Direct ammonia shunting to systemic circulation |
Cerebral Oedema in Acute Liver Failure
Epidemiology and Risk Factors
Cerebral oedema is a major cause of death in ALF, occurring in 20-30% of patients with Grade III-IV HE (PMID: 14714165):
High Risk:
- Grade III-IV hepatic encephalopathy
- Arterial ammonia >150-200 μmol/L
- Hyperacute liver failure (especially paracetamol, hepatitis A/B)
- Young age
- Rapidly rising ammonia
- Need for vasopressors
- SIRS/infection
Lower Risk:
- Subacute liver failure
- Non-paracetamol aetiology (some)
- Older age
Pathophysiology: Cytotoxic vs Vasogenic Oedema
Cerebral oedema in ALF is predominantly cytotoxic (intracellular), in contrast to many other causes of cerebral oedema (PMID: 25042402):
| Feature | Cytotoxic Oedema (ALF) | Vasogenic Oedema |
|---|---|---|
| Location | Intracellular (astrocyte swelling) | Extracellular |
| BBB integrity | Intact (early) | Disrupted |
| Mechanism | Glutamine accumulation, osmotic stress | BBB breakdown, plasma extravasation |
| MRI appearance | Restricted diffusion (DWI bright, ADC dark) | T2 hyperintensity, normal diffusion |
| White vs grey matter | Grey matter predominant (astrocyte-rich) | White matter predominant |
The "Trojan Horse" Hypothesis
Glutamine acts as a "Trojan horse" for ammonia toxicity (PMID: 17428996):
- Ammonia is incorporated into glutamine in astrocyte cytoplasm
- Glutamine is transported into mitochondria
- Mitochondrial glutaminase cleaves glutamine → releases ammonia inside mitochondria
- High intra-mitochondrial ammonia → mPTP opening → oxidative stress → mitochondrial dysfunction
- This amplifies cellular energy failure and swelling
Intracranial Hypertension and Herniation
Monro-Kellie Doctrine
The skull is a rigid container; its contents (brain ~80%, blood ~10%, CSF ~10%) must remain constant. Cerebral oedema increases brain volume, initially compensated by CSF displacement and reduced venous blood. When compensation is exhausted, ICP rises exponentially.
Clinical Features of Raised ICP
| Feature | Mechanism |
|---|---|
| Cushing's response | Hypertension + bradycardia + irregular respirations (late sign) |
| Pupillary changes | Unilateral then bilateral dilation (CN III compression) |
| Decerebrate posturing | Brainstem dysfunction |
| Loss of brainstem reflexes | Progressive herniation |
| Hyperventilation then apnoea | Initially compensatory, then brainstem failure |
Cerebral Perfusion Pressure
CPP = MAP - ICP
- Target CPP: >60 mmHg
- Target ICP: <25 mmHg (or <20 mmHg in severe cases)
- Autoregulation often impaired in ALF - CPP-dependent cerebral blood flow
Management of Cerebral Oedema in ALF
ICP Monitoring (controversial):
- Consider in Grade III-IV HE with high-risk features
- Epidural or intraparenchymal (subdural has higher bleeding risk)
- Coagulopathy correction to INR <1.5 or platelets >50 recommended
- Limited evidence for mortality benefit but aids management decisions
Therapeutic Interventions:
| Tier | Intervention | Target |
|---|---|---|
| General | Head elevation 30°, sedation, avoid hyperthermia, avoid hypoxia/hypercapnia, treat seizures | Prevent secondary injury |
| Tier 1 | Osmotherapy (mannitol 0.5-1 g/kg or hypertonic saline 3% 2-5 mL/kg) | ICP <25, serum Na 145-155 |
| Tier 2 | Hypothermia (32-35°C) - reduces ammonia production and cerebral metabolism | Core temp 33-34°C |
| Tier 3 | Barbiturate coma (rarely used), indomethacin (reduces CBF) | Last resort |
| Ammonia-lowering | Lactulose, rifaximin (limited acute evidence); CRRT for refractory hyperammonaemia | Ammonia <100 |
Metabolic Derangements
Hypoglycaemia
Hypoglycaemia is a common and dangerous complication of ALF (PMID: 21757548):
Mechanisms
| Mechanism | Explanation |
|---|---|
| Impaired gluconeogenesis | Liver is primary site of gluconeogenesis; hepatocyte loss reduces capacity |
| Depleted glycogen stores | Initial hepatocyte damage depletes stored glycogen |
| Hyperinsulinaemia | Reduced hepatic insulin clearance → elevated insulin levels |
| Increased glucose utilisation | Hypermetabolic state, sepsis, regenerating hepatocytes |
Clinical Implications
- May be severe, recurrent, and refractory
- Can cause or worsen encephalopathy
- Monitor blood glucose every 1-2 hours initially
- Continuous glucose infusion (10-20% dextrose) often required
- Target: Blood glucose 6-10 mmol/L
Lactate and Acid-Base Disturbances
Lactic Acidosis in ALF
Lactate elevation in ALF has multiple mechanisms (PMID: 20190714):
- Impaired lactate clearance: Liver normally clears 70% of circulating lactate
- Increased production: Tissue hypoxia (hyperdynamic shock), SIRS, anaerobic glycolysis
- Hypoperfusion: Cardiogenic or distributive shock component
Prognostic significance:
- Lactate >3.5 mmol/L after resuscitation is a poor prognostic sign
- Included in modified King's College Criteria
- Lactate >3.0 mmol/L at 12 hours post-NAC initiation (paracetamol) predicts poor outcome (PMID: 20190714)
Acid-Base Patterns
| Pattern | Mechanism | When Seen |
|---|---|---|
| Metabolic acidosis (lactic) | Impaired lactate clearance, tissue hypoperfusion | Severe ALF, shock |
| Respiratory alkalosis | Central hyperventilation (ammonia effect on brainstem) | Common early finding |
| Metabolic alkalosis | Vomiting, NG losses, diuretics | Variable |
| Mixed | Combination of above | Advanced ALF |
Electrolyte Disturbances
| Electrolyte | Abnormality | Mechanism |
|---|---|---|
| Sodium | Hyponatraemia | Dilutional (ADH excess), free water retention |
| Potassium | Hypokalaemia | Losses (vomiting, diarrhoea), alkalosis, insulin (glucose) |
| Phosphate | Hypophosphataemia | Glucose infusion, refeeding, regeneration (high demand) |
| Magnesium | Hypomagnesaemia | Losses, poor intake |
| Calcium | Hypocalcaemia | Citrate (if massive transfusion), hypoalbuminaemia |
Phosphate is critical for ATP production and hepatocyte regeneration. Profound hypophosphataemia can limit recovery and is associated with poor prognosis if not corrected. In contrast, rising phosphate levels without replacement may indicate failed regeneration (no phosphate consumption by regenerating cells).
Haemodynamic Changes
Hyperdynamic Circulation
ALF produces a circulatory pattern remarkably similar to sepsis (PMID: 15671025):
| Parameter | Direction | Typical Values |
|---|---|---|
| Systemic vascular resistance (SVR) | ↓↓ | 500-1000 dyn·s/cm⁵ (normal 900-1400) |
| Cardiac output (CO) | ↑↑ | Increased 50-100% |
| Mean arterial pressure (MAP) | ↓ | Often requires vasopressor support |
| Pulmonary vascular resistance | ↓ | Variable |
| Mixed venous O₂ saturation | ↑ | >75% (impaired O₂ extraction) |
| Oxygen consumption (VO₂) | ↓ | Supply-independent (early) to supply-dependent |
Mechanisms of Vasodilation
| Mediator | Source | Effect |
|---|---|---|
| Nitric oxide (NO) | iNOS upregulation (endothelium, macrophages) | Potent vasodilator |
| Prostacyclin (PGI₂) | Endothelium | Vasodilation, platelet inhibition |
| Endotoxin (LPS) | Gut translocation (bacterial) | iNOS induction, cytokine release |
| Cytokines (TNF-α, IL-1, IL-6) | Macrophages, hepatocytes | Vascular dysfunction |
| Carbon monoxide (CO) | Heme oxygenase induction | Vasodilation |
Portal Hypertension in ALF
Unlike chronic liver disease, portal hypertension in ALF develops acutely (PMID: 21757548):
Mechanisms:
- Sinusoidal obstruction: Hepatocyte swelling compresses sinusoids
- Regenerative nodule formation: Disrupts normal architecture
- Inflammatory infiltration: Adds to sinusoidal resistance
- Microvascular thrombosis: DIC component
Consequences (often less pronounced than chronic portal hypertension):
- Ascites (usually mild)
- Gut oedema and ileus
- Contributes to bacterial translocation
Cardiac Dysfunction
High-output cardiac failure:
- Hyperdynamic but relative cardiac insufficiency
- Similar to septic cardiomyopathy
Specific abnormalities:
- QT prolongation (metabolic, drug effects)
- Arrhythmias (electrolyte disturbances)
- Subclinical myocardial depression (circulating depressant factors)
Adrenal insufficiency:
- Relative adrenal insufficiency common in severe ALF
- Impaired cortisol response to ACTH
- Consider stress-dose hydrocortisone in refractory shock
Hepatorenal Syndrome
Definition
Hepatorenal syndrome (HRS) is functional renal failure in patients with advanced liver disease, in the absence of intrinsic renal pathology (PMID: 26254576):
Diagnostic criteria (ICA 2015):
- Cirrhosis with ascites OR acute liver failure
- Diagnosis of AKI (increase in creatinine ≥26.5 μmol/L within 48 hours or ≥50% within 7 days)
- No improvement after 2 days of diuretic withdrawal and albumin expansion (1 g/kg/day, max 100 g/day)
- Absence of shock
- No current or recent nephrotoxic drugs
- No parenchymal kidney disease (proteinuria <500 mg/day, microhaematuria <50 RBCs/hpf, normal renal ultrasound)
Classification
| Type | Clinical Features | Prognosis |
|---|---|---|
| HRS-AKI (Type 1) | Rapid progression: doubling of creatinine to >226 μmol/L in <2 weeks | Median survival 2 weeks without treatment |
| HRS-NAKI (Type 2) | Slower progression, often stable | Median survival 6 months; usually with refractory ascites |
Pathophysiology
The "arterial vasodilation hypothesis" explains HRS development (PMID: 15915323):
Step 1: Splanchnic Vasodilation
- Portal hypertension → splanchnic NO and prostacyclin release
- Splanchnic arterial vasodilation → blood pooling in mesenteric circulation
- Reduced effective arterial blood volume (EABV)
Step 2: Compensatory Activation
- Baroreceptors sense reduced EABV
- Activation of:
- Renin-angiotensin-aldosterone system (RAAS)
- Sympathetic nervous system (SNS)
- Arginine vasopressin (AVP)
Step 3: Renal Vasoconstriction
- Angiotensin II, noradrenaline, ADH cause renal arterial vasoconstriction
- Decreased renal blood flow (despite normal kidney structure)
- Reduced GFR → oliguric renal failure
Step 4: Failure of Compensation
- Cardiac output eventually fails to compensate for vasodilation
- Progressive renal hypoperfusion despite maximal vasoconstriction
- Worsening sodium and water retention → further ascites
HRS in Acute Liver Failure (vs Cirrhosis)
HRS in ALF differs from cirrhotic HRS:
| Feature | HRS in ALF | HRS in Cirrhosis |
|---|---|---|
| Portal hypertension | Acute, less severe | Chronic, established |
| Ascites | Usually mild | Usually prominent |
| Reversibility | May reverse with liver recovery/transplant | Rarely reverses without transplant |
| Pathophysiology | Systemic inflammation dominant | Splanchnic vasodilation dominant |
| Additional factors | Nephrotoxins (paracetamol metabolites), ATN component | More purely functional |
Differential Diagnosis of AKI in ALF
| Diagnosis | Features | Urinalysis | FENa |
|---|---|---|---|
| HRS | Functional, reversible with transplant | Bland | <1% |
| Pre-renal azotaemia | Responds to volume | Bland | <1% |
| ATN | Often from paracetamol, hypotension, sepsis | Granular casts, tubular cells | >2% |
| Contrast nephropathy | Post-contrast exposure | Bland | Variable |
| Abdominal compartment syndrome | Tense ascites, raised IAP | Bland | Variable |
SIRS and Sepsis in Acute Liver Failure
Immune Dysfunction in ALF
ALF causes a complex immune derangement with both hyperinflammation and immunodeficiency (PMID: 22972682):
Pro-inflammatory (SIRS) features:
- Elevated TNF-α, IL-1β, IL-6
- Activated complement
- SIRS criteria met in 50-60% of ALF patients
- Systemic endotoxaemia from gut translocation
Immunodeficiency features:
- Reduced complement synthesis (C3, C4, C5) - liver synthesises most complement
- Impaired opsonisation
- Kupffer cell dysfunction
- Reduced neutrophil chemotaxis and phagocytosis
- Lymphocyte dysfunction
- Reduced immunoglobulin production
Clinical consequence: Patients have SIRS-like physiology but are highly susceptible to infection
Infection in ALF
Infection is common (50-80%) and is a major cause of morbidity and mortality (PMID: 22972682):
Common Organisms
| Site | Common Organisms |
|---|---|
| Respiratory | Staphylococcus aureus, Streptococcus pneumoniae, Gram-negative bacilli |
| Bloodstream | Staphylococcus (lines), enteric Gram-negatives, Candida species |
| Urinary | Escherichia coli, Klebsiella, Enterococcus |
| Intra-abdominal | Enteric Gram-negatives, Candida |
Risk Factors for Infection
- Grade III-IV encephalopathy
- Prolonged ICU stay
- Multiple invasive devices (CVC, IDC, ETT)
- Renal replacement therapy
- Paracetamol aetiology (less immunocompromised than other causes)
- Need for vasopressors
Prophylactic Antibiotics
Controversial practice - no high-quality RCTs
Arguments for:
- High infection rate (50-80%)
- Infection worsens prognosis
- May prevent bacteraemia triggering cytokine storm
Arguments against:
- Promotes resistance
- May not improve outcomes
- Many infections are fungal
Current practice (varies by centre):
- Some centres use routine prophylaxis (e.g., piperacillin-tazobactam + fluconazole)
- Others reserve antibiotics for proven/suspected infection
- Antifungal prophylaxis considered in high-risk cases
Surveillance cultures (respiratory, urine, blood) recommended every 48-72 hours.
Sepsis Mimicry
ALF can mimic sepsis clinically, making infection diagnosis challenging:
| Feature | ALF without Infection | Sepsis |
|---|---|---|
| Fever | Common (necrosis-related) | Common |
| Leukocytosis | Common | Common |
| Elevated PCT | May be elevated | Typically elevated |
| Lactate | Often elevated | Often elevated |
| Vasopressor need | Common | Common |
| Cultures | Negative | Positive (ideally) |
Approach: High index of suspicion; low threshold for empiric antibiotics; repeat cultures.
Hepatic Regeneration
Overview of Liver Regeneration
The liver has remarkable regenerative capacity, able to restore original mass after 70% hepatectomy within 2-3 weeks (PMID: 17245125):
Types of regeneration:
- Hepatocyte-driven: Mature hepatocytes proliferate (primary mechanism)
- Progenitor cell (oval cell) activation: Hepatic progenitor cells differentiate (when hepatocyte proliferation impaired)
Regeneration vs hyperplasia:
- True regeneration: Restoration of original structure AND function
- Liver regeneration is technically "compensatory hyperplasia"
- remaining hepatocytes enlarge and divide
Hepatocyte Proliferation
Initiation Phase (0-5 hours post-injury)
| Factor | Source | Role |
|---|---|---|
| TNF-α | Kupffer cells | "Priming" |
- makes hepatocytes competent to respond | | IL-6 | Kupffer cells, endothelium | Activates STAT3 → immediate early genes | | Complement (C3a, C5a) | Liver synthesis, activation | Promotes IL-6 release, NF-κB activation | | LPS | Gut (via portal vein) | TLR4 activation → TNF-α release |
Progression Phase (Growth Factors)
| Growth Factor | Source | Mechanism |
|---|---|---|
| HGF (Hepatocyte Growth Factor) | Stellate cells, endothelium | c-Met receptor → potent mitogen |
| EGF/TGF-α | Salivary glands, macrophages | EGFR → proliferation |
| VEGF | Multiple | Angiogenesis to support new tissue |
| Insulin | Pancreas | Metabolic support, permissive |
Termination Phase
| Factor | Mechanism |
|---|---|
| TGF-β | Inhibits hepatocyte proliferation |
| Activin A | Growth arrest |
| Contact inhibition | Cell-cell contact restores quiescence |
| Restoration of mass | Signals (unclear) sense adequate regeneration |
Progenitor Cell (Oval Cell) Response
When hepatocyte proliferation is impaired (e.g., massive necrosis, chronic injury), hepatic progenitor cells are activated (PMID: 23392622):
Hepatic progenitor cells (HPCs):
- Location: Canals of Hering (junction of bile canaliculi and bile ducts)
- Bipotential: Can differentiate into hepatocytes OR cholangiocytes
- Also called "oval cells" (rodents), "reactive ductular cells" (humans)
Activation signals:
- Wnt/β-catenin pathway
- Notch signaling
- Hedgehog pathway
- FGF signaling
Ductular reaction: Proliferation of small ductular structures at portal margins - histological evidence of progenitor activation
Factors Affecting Regeneration in ALF
| Factor | Effect on Regeneration |
|---|---|
| Age | Elderly have reduced regenerative capacity |
| Nutritional status | Malnutrition impairs regeneration |
| Infection/sepsis | Inflammatory cytokines shift from regeneration to acute phase response |
| Ongoing toxin exposure | Continued injury prevents recovery |
| Aetiology | Paracetamol (single insult) regenerates better than subacute causes |
| Haemodynamic stability | Hypoperfusion impairs regeneration |
| Phosphate levels | Hypophosphataemia limits ATP for regeneration |
In recovering ALF, serum phosphate typically FALLS as regenerating hepatocytes consume phosphate for ATP synthesis. Persistent hypophosphataemia (requiring replacement) may indicate active regeneration. In contrast, stable or rising phosphate without replacement may suggest failure of regeneration (poor prognosis).
Histopathology
Patterns of Hepatic Necrosis
The histopathological pattern provides aetiological and prognostic information (PMID: 24905494):
| Pattern | Description | Common Causes |
|---|---|---|
| Centrilobular (Zone 3) | Necrosis around central veins, periportal sparing | Paracetamol, hypoxia/ischaemia, heart failure, CCl₄ |
| Periportal (Zone 1) | Necrosis around portal tracts | Phosphorus poisoning, eclampsia, some drugs |
| Midzonal (Zone 2) | Necrosis in intermediate zone (rare) | Yellow fever |
| Bridging necrosis | Necrosis connecting portal-central OR portal-portal | Severe viral hepatitis, autoimmune |
| Panacinar (massive) | Complete acinar necrosis | Fulminant ALF of any cause |
| Submassive | Extensive but not complete; some viable hepatocytes remain | Severe but potentially recoverable |
Microscopic Features
Acute Phase
| Feature | Description |
|---|---|
| Hepatocyte necrosis | Eosinophilic cytoplasm, pyknotic nuclei, karyorrhexis |
| Hepatocyte dropout | Empty spaces, reticulin collapse |
| Ballooning degeneration | Swollen hepatocytes (pre-necrotic) |
| Apoptotic bodies | Shrunken, eosinophilic cells with fragmented nuclei (Councilman bodies) |
| Cholestasis | Bile plugs in canaliculi |
| Inflammatory infiltrate | Lymphocytes, neutrophils, macrophages |
| Kupffer cell hyperplasia | Activated Kupffer cells, often containing debris |
Regenerative Phase
| Feature | Description |
|---|---|
| Hepatocyte mitoses | Dividing hepatocytes |
| Hepatocyte rosettes | Regenerating hepatocytes arranged in circular pattern |
| Thick cell plates | More than 2-cell-thick plates |
| Ductular reaction | Proliferation of ductular structures (progenitor activation) |
| Nodular regeneration | If survival; may progress to cirrhosis if chronic |
Specific Histopathological Patterns by Aetiology
| Aetiology | Characteristic Features |
|---|---|
| Paracetamol | Centrilobular confluent necrosis, sharp demarcation from viable tissue |
| Viral hepatitis | Spotty necrosis (scattered), Councilman bodies, portal/lobular inflammation |
| Autoimmune | Interface hepatitis, plasma cells, "rosettes" |
| Wilson's disease | Glycogenated nuclei, copper stains (rhodanine, orcein), Mallory-Denk bodies |
| AFLP | Microvesicular steatosis, minimal inflammation |
| Drug-induced | Variable; may have eosinophils, granulomas, cholestasis |
| Ischaemic | Centrilobular necrosis with "ghost" hepatocytes, minimal inflammation |
Prognostic Scoring
King's College Criteria (1989)
The most widely used criteria for transplant listing in ALF (PMID: 2490426):
PARACETAMOL-Induced ALF:
- pH <7.30 after adequate fluid resuscitation (strongest predictor)
OR ALL THREE of:
- INR >6.5 (or PT >100 seconds)
- Serum creatinine >300 μmol/L (>3.4 mg/dL)
- Grade III or IV hepatic encephalopathy
NON-PARACETAMOL ALF:
- INR >6.5 (or PT >100 seconds) alone
OR ANY THREE of the following:
- Age <10 or >40 years
- Aetiology: non-A non-B hepatitis OR idiosyncratic drug reaction
- Duration of jaundice before encephalopathy >7 days
- INR >3.5 (or PT >50 seconds)
- Serum bilirubin >300 μmol/L (>17.5 mg/dL)
Interpretation: Meeting criteria indicates poor prognosis without transplant; consider urgent transplant listing.
Performance of King's College Criteria
| Measure | Paracetamol | Non-Paracetamol |
|---|---|---|
| Sensitivity | 58-69% | 68-82% |
| Specificity | 79-95% | 76-92% |
| PPV | 79-95% | 73-97% |
| NPV | 50-79% | 81-98% |
Limitations:
- Developed in 1989; medical management has improved
- Does not account for aetiology-specific factors (e.g., Wilson's)
- May miss patients who would benefit from transplant
Modified King's College Criteria (with Lactate)
Addition of lactate improves sensitivity for paracetamol ALF (PMID: 20190714):
Lactate criteria:
- Arterial lactate >3.5 mmol/L after early fluid resuscitation (4 hours) OR
- Arterial lactate >3.0 mmol/L after full fluid resuscitation (12 hours)
MELD Score (Model for End-Stage Liver Disease)
Originally developed for cirrhosis, MELD is also used in ALF (PMID: 11172350):
MELD = 3.78 \times \ln(bilirubin) + 11.2 \times \ln(INR) + 9.57 \times \ln(creatinine) + 6.43
Bilirubin and creatinine in mg/dL; minimum values 1.0
| MELD Score | 3-Month Mortality |
|---|---|
| <10 | 1.9% |
| 10-19 | 6% |
| 20-29 | 19.6% |
| 30-39 | 52.6% |
| ≥40 | 71.3% |
In ALF: MELD may be comparable to King's criteria for prognosis; used for transplant allocation in many jurisdictions.
Other Prognostic Markers
| Marker | Significance |
|---|---|
| Factor V <20% | Very poor prognosis (Clichy criteria) |
| Ammonia >200 μmol/L | High risk of cerebral oedema and death |
| Phosphate rising (without replacement) | Failure of regeneration |
| APACHE II/III | General severity score; validated in ALF |
| α-fetoprotein (AFP) rising | May indicate hepatocyte regeneration (favourable) |
| Gc-globulin (vitamin D binding protein) | Low levels predict poor outcome |
Australian/New Zealand Context
ALF Epidemiology in Australia
Incidence: Approximately 250 cases of ALF annually in Australia
Aetiology Distribution:
- Paracetamol: 50-60%
- Drug-induced (non-paracetamol): 10-15%
- Viral hepatitis: 10-15%
- Indeterminate: 10-15%
- Other (Wilson's, autoimmune, vascular): 5-10%
Liver Transplant Centres:
- Royal Prince Alfred Hospital (NSW)
- Austin Hospital (VIC)
- Princess Alexandra Hospital (QLD)
- Sir Charles Gairdner Hospital (WA)
- Flinders Medical Centre (SA)
New Zealand:
- Auckland City Hospital (only NZ liver transplant centre)
Paracetamol Overdose Patterns in Australia
Paracetamol poisoning has distinct patterns in Australia:
Demographics:
- Peak age: 15-35 years
- Female predominance (intentional overdose)
- Often associated with alcohol co-ingestion
Therapeutic misadventure:
- Significant proportion of ALF from staggered/therapeutic overdose
- Often involves multiple paracetamol-containing products
- Associated with chronic pain, poor health literacy
Combination products:
- Paracetamol combined with opioids (codeine, oxycodone)
- Paracetamol combined with antihistamines (cold preparations)
- Patients may not recognise paracetamol content
Retrieval and Transfer
Principles:
- Early contact with liver transplant unit (before meeting KCC)
- Transfer to transplant centre when Grade II+ HE or meeting KCC
- Retrieval services: NETS, CareFlight, Adult Retrieval Victoria, RFDS
Pre-transfer stabilisation:
- Secure airway if Grade III-IV HE
- Blood glucose management
- Coagulopathy correction only for active bleeding/procedures
- NAC continuation if paracetamol
- ICP management if cerebral oedema suspected
Indigenous Health Considerations
Aboriginal and Torres Strait Islander Peoples
Epidemiological Considerations:
- Higher rates of hepatitis B infection (particularly in Northern Australia and remote communities)
- HBV-related ALF can occur with reactivation during immunosuppression or treatment non-adherence
- Limited data on paracetamol ALF specifically in Indigenous populations
- Higher burden of chronic liver disease (alcohol-related, viral) - though these cause ACLF rather than ALF
- Hepatitis A outbreaks in remote communities (vaccination programs have improved this)
Healthcare Access Challenges:
- Geographic isolation may delay presentation
- Limited access to tertiary hepatology/ICU services
- Transfer to distant liver transplant centres separates patients from family and Country
- Retrieval logistics in remote areas (RFDS essential)
Cultural Considerations:
- Family and community involvement in major medical decisions essential
- Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs) should be involved
- Cultural protocols around serious illness and potential death
- Men's and women's business considerations
- Language interpreters for non-English speakers
- Understanding of health concepts may differ - use appropriate health literacy approaches
- "Sorry Business" and cultural obligations may affect family availability
- Connection to Country important for healing and wellbeing
Transplant Considerations:
- Relocation to transplant centre (major cities) involves separation from Country and community
- Long-term immunosuppression adherence challenges
- Regular follow-up appointments distant from home
- Support structures (accommodation, transport, family support) crucial
- Post-transplant care pathways back to community require coordination
Māori Health (New Zealand)
Epidemiological Considerations:
- Higher rates of viral hepatitis (hepatitis B)
- May have delayed presentation due to healthcare access barriers
- Limited data on ALF specifically in Māori population
Cultural Considerations:
- Whānau (extended family) central to all decision-making - involve early and throughout
- Kaumātua (elders) may need to be present for major decisions
- Tikanga Māori (cultural practices) should be respected
- Te reo Māori (Māori language) services as needed
- Karakia (prayers/blessings) may be requested
- Understanding of Māori health models (Te Whare Tapa Whā - holistic wellbeing)
- Māori Health Workers involvement
- Manaakitanga (care, hospitality) principles in healthcare delivery
Te Tiriti o Waitangi Obligations:
- Ensure equitable access to liver transplant services
- Partnership in care decisions
- Protection of Māori health outcomes
- Address systemic barriers to care
SAQ Practice Questions
Question: Describe the pathophysiology of paracetamol-induced hepatotoxicity, including the mechanisms of hepatocyte death and the concept of hepatic zonality. (15 marks)
Model Answer
1. Introduction and Clinical Context (1 mark)
Paracetamol hepatotoxicity results from the accumulation of a toxic metabolite, NAPQI, when detoxification pathways are overwhelmed. The patient has ingested approximately 25 g of paracetamol, which is a severely hepatotoxic dose (>200 mg/kg).
2. Normal Paracetamol Metabolism (3 marks)
Primary pathways (90%):
- Glucuronidation via UGT enzymes (55%)
- Sulfation via SULT enzymes (35%)
- Both produce non-toxic water-soluble metabolites for renal excretion
Secondary pathway (5-10%):
- Cytochrome P450 oxidation (primarily CYP2E1, also CYP1A2 and CYP3A4)
- Produces NAPQI (N-acetyl-p-benzoquinone imine) - a highly reactive, toxic metabolite
Detoxification of NAPQI:
- NAPQI is rapidly conjugated with glutathione (GSH)
- Forms non-toxic mercapturic acid for renal excretion
- Requires adequate hepatic glutathione stores
3. Toxicity in Overdose - NAPQI Accumulation (4 marks)
Phase 1: Glutathione depletion
- Glucuronidation and sulfation pathways become saturated
- Increased CYP450 metabolism → more NAPQI generated
- Glutathione consumed faster than regenerated
- Critical threshold: >70% GSH depletion
Phase 2: Protein adduct formation
- Excess NAPQI binds covalently to cellular proteins (cysteine residues)
- Particularly targets mitochondrial proteins
- Protein adducts disrupt enzyme function
Phase 3: Mitochondrial dysfunction
- Impaired electron transport chain (especially Complex I)
- Decreased ATP production
- Increased reactive oxygen species (ROS) generation
- Opening of mitochondrial permeability transition pore (mPTP)
Phase 4: Amplification by JNK
- ROS activate c-Jun N-terminal kinase (JNK) in cytoplasm
- Activated JNK translocates to mitochondria
- JNK amplifies mitochondrial oxidative stress
- Creates positive feedback loop of injury
4. Mechanisms of Hepatocyte Death (3 marks)
Necrosis (predominant in severe toxicity):
- ATP depletion prevents active cell death pathways
- Loss of ion homeostasis (Na⁺/K⁺-ATPase failure)
- Cellular swelling and membrane rupture
- Release of DAMPs → sterile inflammation
- Karyolysis (nuclear dissolution)
Apoptosis (if ATP partially preserved):
- Cytochrome c release from mitochondria → activates caspase-9
- Caspase-9 activates caspase-3 (executioner caspase)
- Controlled cell death with formation of apoptotic bodies
- Less inflammatory response
Regulated necrosis (necroptosis):
- RIPK1/RIPK3/MLKL pathway may contribute
- Programmed necrotic death when caspases inhibited
5. Hepatic Zonality (3 marks)
Liver acinus structure:
- Functional unit organised around portal triad and central vein
- Blood flows from Zone 1 (periportal) → Zone 2 → Zone 3 (centrilobular)
Zone 3 (centrilobular) characteristics:
- Highest CYP2E1 concentration → most NAPQI generated
- Lowest oxygen tension (venous end of sinusoid) → vulnerable to hypoxia
- Lowest glutathione levels → least capacity for NAPQI detoxification
- Lowest NADPH → impaired GSH regeneration
Histological pattern:
- Centrilobular (Zone 3) necrosis characteristic of paracetamol toxicity
- May progress to bridging necrosis (Zone 3 to Zone 3) in severe cases
- Eventually massive/panacinar necrosis in fulminant disease
- Zone 1 (periportal) relatively spared
6. Clinical Implications (1 mark)
- N-acetylcysteine (NAC) is the antidote: replenishes glutathione, provides antioxidant effects, supports mitochondrial function
- Most effective within 8-10 hours but beneficial up to 24+ hours
- Zone 3 pattern on biopsy confirms paracetamol aetiology
- Severity of Zone 3 necrosis correlates with clinical severity
Question: Describe the pathophysiology of hepatic encephalopathy and cerebral oedema in acute liver failure. Explain why ALF patients are at higher risk of cerebral oedema than patients with chronic liver disease. (15 marks)
Model Answer
1. Introduction (1 mark)
Hepatic encephalopathy (HE) in acute liver failure (ALF) represents a neuropsychiatric syndrome caused primarily by hyperammonaemia. Unlike chronic liver disease, ALF carries a high risk of cerebral oedema and intracranial hypertension due to the acute nature of the metabolic insult.
2. Ammonia Metabolism and Accumulation (3 marks)
Normal ammonia handling:
- Sources: Gut bacteria (urease), enterocyte glutaminase, renal ammoniagenesis, muscle deamination
- Absorbed from colon into portal circulation
- 85% cleared by periportal hepatocytes via urea cycle (ornithine transcarbamylase pathway)
- Remaining ammonia: perivenous hepatocytes convert to glutamine (glutamine synthetase)
- Normal arterial ammonia: <50 μmol/L
In liver failure:
- Massive hepatocyte loss → reduced urea cycle capacity
- Porto-systemic shunting → ammonia bypasses liver
- Increased renal ammoniagenesis (due to hypokalemia, alkalosis common in ALF)
- Arterial ammonia rises (this patient: 185 μmol/L - severely elevated)
3. The Ammonia-Glutamine-Astrocyte Swelling Pathway (4 marks)
Step 1: Blood-brain barrier crossing
- Ammonia exists in equilibrium: NH₃ (un-ionised) ⇌ NH₄⁺ (ionised)
- Only NH₃ freely crosses the blood-brain barrier
- Alkalosis favours NH₃ form → increased CNS penetration
- In ALF, massive systemic ammonia overcomes normal BBB buffering
Step 2: Astrocyte uptake and glutamine synthesis
- Ammonia enters astrocytes (NOT neurons - neurons lack glutamine synthetase)
- Glutamine synthetase catalyses: Glutamate + NH₃ → Glutamine
- This is the ONLY pathway for ammonia detoxification in the CNS
- Glutamine accumulates within astrocytes
Step 3: Osmotic stress and astrocyte swelling
- Glutamine is osmotically active
- Water enters astrocytes → cellular swelling
- This is CYTOTOXIC oedema (intracellular)
- Astrocyte swelling is the hallmark of HE in ALF
Step 4: "Trojan horse" mitochondrial toxicity
- Glutamine transported into astrocyte mitochondria
- Mitochondrial glutaminase cleaves glutamine → releases ammonia INSIDE mitochondria
- High intra-mitochondrial ammonia → mPTP opening → oxidative stress
- Mitochondrial dysfunction → impaired astrocyte energy metabolism
- Amplifies cellular dysfunction beyond osmotic effects alone
4. Additional Mechanisms of Hepatic Encephalopathy (2 marks)
| Mechanism | Contribution |
|---|---|
| Neuroinflammation | Systemic inflammation (SIRS) → microglial activation, BBB dysfunction; synergises with ammonia |
| GABA-ergic tone | Increased endogenous benzodiazepine-like substances; increased GABA receptor sensitivity |
| False neurotransmitters | Aromatic amino acids (phenylalanine, tyrosine, tryptophan) cross BBB; compete with catecholamine synthesis |
| Manganese | Normally excreted in bile; accumulates in basal ganglia → T1 MRI hyperintensity |
| Oxidative stress | Direct ammonia and inflammatory-mediated neuronal oxidative damage |
5. Cerebral Oedema: Cytotoxic vs Vasogenic (3 marks)
Cytotoxic oedema (predominant in ALF):
- Intracellular fluid accumulation (astrocyte swelling)
- Blood-brain barrier remains INTACT (at least initially)
- Mechanism: glutamine accumulation → osmotic stress
- MRI: Restricted diffusion (DWI bright, ADC dark)
- Predominantly affects grey matter (astrocyte-rich)
Vasogenic oedema (less prominent initially):
- Extracellular fluid accumulation
- Requires BBB breakdown
- May develop later in severe cases
- Predominantly affects white matter
In ALF: Primarily cytotoxic mechanism, unlike traumatic brain injury or stroke where vasogenic oedema predominates.
6. Why ALF Has Higher Cerebral Oedema Risk Than Chronic Liver Disease (2 marks)
| Factor | Acute Liver Failure | Chronic Liver Disease |
|---|---|---|
| Ammonia rise | Acute, rapid | Gradual, chronic |
| Astrocyte adaptation | No time to adapt | Astrocytes develop compensatory mechanisms (osmolyte extrusion) |
| Glutamine accumulation | Rapid, overwhelming | Chronic low-grade elevation |
| Inflammatory component | Severe SIRS, acute inflammation | Less acute inflammation |
| Systemic illness | Multi-organ failure, cytokine storm | More stable systemic state |
| Osmolyte compensation | None | Astrocytes extrude myo-inositol, taurine to maintain volume |
Chronic adaptation: In chronic liver disease, astrocytes upregulate volume regulatory mechanisms - they export organic osmolytes (myo-inositol, taurine, glycerophosphocholine) to compensate for glutamine accumulation. This adaptation takes weeks to develop and is absent in ALF.
Clinical significance: Cerebral oedema complicates 20-30% of Grade III-IV HE in ALF but is rare in chronic liver disease. Ammonia >150-200 μmol/L in ALF is a major risk factor for intracranial hypertension and herniation.
Viva Practice Scenarios
Stem: "A 38-year-old woman with acute liver failure from paracetamol overdose has an INR of 7.2. The surgical team is concerned about placing a central venous catheter due to bleeding risk."
Examiner: "Tell me about the coagulopathy in acute liver failure."
Candidate: "Acute liver failure causes a complex coagulopathy due to impaired hepatic synthesis. The liver produces virtually all coagulation factors except Factor VIII and von Willebrand factor, which are produced by endothelium.
The procoagulant factors with shortest half-lives are affected earliest:
- Factor VII has a half-life of only 4-6 hours, explaining why INR rises rapidly
- Factor II (prothrombin), V, IX, and X are also reduced
- Fibrinogen may be normal initially due to the acute phase response
However, I would emphasise that the coagulopathy in ALF is more complex than simple factor deficiency..."
Examiner: "Go on - what do you mean by 'more complex'?"
Candidate: "The concept of 'rebalanced haemostasis' is now recognised as crucial to understanding coagulation in liver failure.
The liver also synthesises the major anticoagulant proteins:
- Protein C (half-life 8 hours) - often profoundly reduced
- Protein S
- Antithrombin
The INR measures ONLY the procoagulant pathway. It does not reflect the parallel reduction in anticoagulants.
Studies using thrombin generation assays and thromboelastography have shown that:
- Global haemostasis may be NORMAL or even pro-thrombotic
- The INR does NOT accurately predict bleeding risk in liver failure
- Patients may be at risk of both bleeding AND thrombosis
The haemostatic balance is precarious - additional insults such as sepsis, renal failure, or procedures can tip the balance in either direction."
Examiner: "So should we give FFP to this patient before central line insertion?"
Candidate: "This is a nuanced decision. Current evidence suggests that routine FFP administration to 'correct' the INR is not indicated for several reasons:
- The INR may not reflect true bleeding risk
- FFP provides both procoagulant AND anticoagulant factors, potentially not changing the balance
- FFP has risks: volume overload, transfusion reactions, TRALI, loss of prognostic information from INR
However, for invasive procedures, many clinicians take a pragmatic approach:
- Consider thromboelastography (TEG/ROTEM) for better assessment of global haemostasis
- Target INR <1.5-2.0 with FFP if TEG suggests coagulopathy
- Use ultrasound guidance to minimise complications
- Consider internal jugular rather than subclavian (compressible if bleeding)
For this patient requiring a CVC, I would:
- Obtain TEG to assess global haemostasis
- Use ultrasound-guided IJ access
- Consider FFP only if TEG shows prolonged clot formation time
- Avoid transfusing to an arbitrary INR target"
Examiner: "What about VTE prophylaxis in this patient?"
Candidate: "This is another area where the concept of rebalanced haemostasis is clinically important.
Despite elevated INR, patients with ALF may not be protected from venous thromboembolism:
- Reduced anticoagulants (Protein C, S, Antithrombin)
- Elevated vWF (endothelial activation, reduced ADAMTS13)
- Reduced mobility, central lines, inflammation - all VTE risk factors
Current practice varies, but many experts recommend:
- Mechanical prophylaxis (graduated compression stockings, pneumatic devices) for all patients
- Pharmacological prophylaxis (LMWH or UFH) can be considered if not actively bleeding
- Assess on individual basis using TEG if available
The key message is that high INR does not equate to 'auto-anticoagulation' in liver failure."
Examiner: "Excellent. Finally, tell me about Factor V levels in ALF."
Candidate: "Factor V has special significance in ALF for several reasons:
- It is synthesised EXCLUSIVELY by the liver (unlike Factor VIII which is endothelial)
- It has an intermediate half-life (12-24 hours)
- It is consumed in DIC, which often complicates ALF
Factor V level <20% is a very poor prognostic marker, reflecting severe synthetic failure. It is used in the Clichy criteria (French prognostic model) for transplant listing.
Factor V is valuable because:
- It reflects both production (hepatocyte mass) and consumption (DIC)
- It is not affected by vitamin K administration (unlike factors II, VII, IX, X)
- Serial measurement may track disease progression or recovery
In this patient with paracetamol ALF, a very low Factor V would suggest severe hepatocyte loss and poor prognosis without transplantation."
Stem: "A 45-year-old man with acute liver failure (subacute, drug-induced) develops oliguria on day 5 of ICU admission. Creatinine has risen from 95 to 280 μmol/L over 48 hours. Urinalysis is bland."
Examiner: "What is the differential diagnosis for acute kidney injury in this patient with acute liver failure?"
Candidate: "The differential for AKI in the context of acute liver failure includes:
-
Hepatorenal syndrome (HRS): Functional renal failure due to splanchnic vasodilation and compensatory renal vasoconstriction - the most concerning diagnosis
-
Pre-renal azotaemia: True volume depletion from:
- GI losses, reduced intake
- Third-spacing (ascites, oedema)
- Haemorrhage
-
Acute tubular necrosis (ATN): From:
- Hypotension/shock
- Nephrotoxins (in paracetamol ALF, NAPQI metabolites may be directly nephrotoxic)
- Sepsis
-
Abdominal compartment syndrome: Raised intra-abdominal pressure from ascites/ileus causing renal venous congestion
-
Nephrotoxic drugs: NSAIDs, aminoglycosides, contrast
The bland urinalysis (no casts, minimal proteinuria) suggests either pre-renal or HRS rather than ATN."
Examiner: "Explain the pathophysiology of hepatorenal syndrome."
Candidate: "Hepatorenal syndrome is explained by the 'arterial vasodilation hypothesis':
Stage 1: Splanchnic Vasodilation
- Portal hypertension (even acute) leads to splanchnic NO and prostacyclin release
- Marked vasodilation of the mesenteric arterial bed
- Blood 'pools' in the splanchnic circulation
- Reduced effective arterial blood volume (EABV) despite normal or increased total blood volume
Stage 2: Compensatory Neurohormonal Activation
- Arterial baroreceptors sense reduced EABV
- Massive activation of:
- Renin-angiotensin-aldosterone system (RAAS)
- Sympathetic nervous system
- Arginine vasopressin (ADH)
Stage 3: Renal Vasoconstriction
- Angiotensin II, noradrenaline, and ADH cause profound renal arterial vasoconstriction
- Reduced renal blood flow and GFR
- Kidneys are structurally NORMAL - the failure is purely functional
Stage 4: Progressive Decompensation
- Eventually cardiac output fails to compensate for peripheral vasodilation
- Worsening effective hypovolaemia despite salt and water retention
- Progressive renal hypoperfusion
The key point is that HRS represents a maldistribution of blood flow - excessive splanchnic vasodilation with compensatory renal vasoconstriction - rather than primary kidney disease."
Examiner: "How would you diagnose HRS in this patient?"
Candidate: "The International Club of Ascites (ICA) 2015 criteria for HRS diagnosis are:
-
Cirrhosis with ascites OR acute liver failure - our patient has ALF
-
Diagnosis of AKI: Increase in creatinine ≥26.5 μmol/L within 48 hours OR ≥50% increase within 7 days - this patient meets criteria (185 μmol/L rise)
-
No improvement after:
- Withdrawal of diuretics (if any)
- Plasma volume expansion with albumin 1 g/kg/day for 2 days (maximum 100 g/day)
-
Absence of shock at time of diagnosis
-
No current or recent nephrotoxic medications
-
No parenchymal kidney disease:
- Proteinuria <500 mg/day
- Microhaematuria <50 RBCs per high-power field
- Normal renal ultrasound
For this patient, I would:
- Review medication chart for nephrotoxins
- Ensure adequate volume status (CVP or dynamic assessment)
- Trial albumin expansion
- Check urinalysis and urine microscopy
- Perform renal ultrasound
- Calculate FENa (expected <1% in HRS, >2% in ATN)
If creatinine does not improve after albumin trial and other criteria are met, HRS is likely."
Examiner: "Is HRS in acute liver failure the same as in cirrhosis?"
Candidate: "There are important differences between HRS in ALF versus cirrhosis:
| Feature | HRS in ALF | HRS in Cirrhosis |
|---|---|---|
| Portal hypertension | Acute, less established | Chronic, severe |
| Ascites | Often mild or absent | Usually prominent |
| Mechanism emphasis | Systemic inflammation (SIRS) plays larger role | Splanchnic vasodilation dominant |
| Nephrotoxic factors | May have ATN component (e.g., paracetamol metabolites) | More purely functional |
| Reversibility | May reverse if liver recovers/transplanted | Rarely reverses without transplant |
| Pharmacotherapy | Limited evidence for terlipressin in ALF | Terlipressin + albumin evidence in cirrhosis |
In ALF, renal failure often has multiple contributing factors - the SIRS response, potential direct nephrotoxicity, and the HRS mechanism all contribute. Recovery of liver function (spontaneously or post-transplant) typically leads to renal recovery, supporting the functional nature.
Treatment options include:
- Supportive care and optimise volume status
- Terlipressin + albumin (extrapolated from cirrhosis data)
- Noradrenaline + albumin (alternative vasoconstrictor)
- Renal replacement therapy if severe
- Liver transplantation - definitive treatment (kidneys usually recover post-transplant)"
MCQ Practice Questions
Question 1
A 28-year-old woman presents 18 hours after ingesting 40 paracetamol tablets. Which zone of the hepatic acinus is most susceptible to paracetamol-induced necrosis?
A. Zone 1 (periportal) B. Zone 2 (intermediate) C. Zone 3 (centrilobular) D. All zones equally affected E. Zone 1 and Zone 2 equally
Answer: C
Explanation: Zone 3 (centrilobular/perivenular) is most susceptible to paracetamol toxicity for several reasons: (1) Highest concentration of CYP2E1, the primary enzyme converting paracetamol to the toxic metabolite NAPQI; (2) Lowest oxygen tension as blood flows from portal (Zone 1) to central (Zone 3); (3) Lowest glutathione levels, reducing capacity to detoxify NAPQI. Histologically, paracetamol overdose shows centrilobular necrosis. Zone 1 is preferentially damaged by phosphorus poisoning. This zonality is a classic CICM First Part concept.
Question 2
Which of the following statements about coagulopathy in acute liver failure is CORRECT?
A. INR accurately predicts bleeding risk in ALF B. Protein C levels are typically preserved while procoagulant factors decrease C. Prophylactic FFP should be given to all patients with INR >2.0 D. Thromboelastography provides better assessment of global haemostasis than INR E. VTE prophylaxis is contraindicated when INR >2.0
Answer: D
Explanation: Thromboelastography (TEG/ROTEM) provides a better assessment of global haemostasis in ALF because it measures the entire coagulation process, including the contribution of both procoagulant and anticoagulant factors. The concept of "rebalanced haemostasis" recognises that INR only measures procoagulant factor reduction, not the parallel reduction in Protein C, Protein S, and Antithrombin. Studies show INR does not accurately predict bleeding risk in liver failure. Routine prophylactic FFP is not recommended. VTE prophylaxis may be appropriate despite elevated INR as patients are not "auto-anticoagulated."
Question 3
In the pathophysiology of hepatic encephalopathy, which cell type is primarily responsible for ammonia detoxification in the central nervous system?
A. Neurons B. Astrocytes C. Microglia D. Oligodendrocytes E. Ependymal cells
Answer: B
Explanation: Astrocytes are the only CNS cells that express glutamine synthetase, the enzyme that converts ammonia and glutamate to glutamine. This is the exclusive pathway for ammonia detoxification in the brain. The accumulation of glutamine within astrocytes creates osmotic stress, leading to astrocyte swelling - the hallmark of hepatic encephalopathy in ALF (cytotoxic oedema). Neurons do NOT have this enzyme and are not directly involved in ammonia metabolism. The "Trojan horse" hypothesis describes how glutamine subsequently enters mitochondria where it releases ammonia, causing further damage.
Question 4
A patient with acute liver failure has Grade IV hepatic encephalopathy. CT brain shows cerebral oedema. Which type of cerebral oedema predominates in acute liver failure?
A. Vasogenic oedema B. Cytotoxic oedema C. Interstitial (hydrocephalic) oedema D. Osmotic oedema E. Mixed vasogenic and interstitial
Answer: B
Explanation: Cerebral oedema in ALF is predominantly CYTOTOXIC (intracellular), caused by astrocyte swelling from glutamine accumulation. The blood-brain barrier remains largely intact, at least initially. This differs from traumatic brain injury or tumours where vasogenic oedema (extracellular, BBB breakdown) predominates. On MRI, cytotoxic oedema shows restricted diffusion (DWI bright, ADC dark). This is why ALF patients are at high risk of cerebral oedema while chronic liver disease patients (who develop compensatory mechanisms) rarely develop significant oedema despite similar ammonia levels.
Question 5
According to the King's College Criteria for paracetamol-induced acute liver failure, which single finding indicates poor prognosis and need for transplant assessment?
A. INR >3.5 B. Bilirubin >300 μmol/L C. pH <7.30 after adequate fluid resuscitation D. Creatinine >200 μmol/L E. Grade II hepatic encephalopathy
Answer: C
Explanation: For paracetamol-induced ALF, pH <7.30 ALONE (after adequate fluid resuscitation) meets King's College Criteria for poor prognosis. Alternatively, ALL THREE of the following are required: INR >6.5 (not 3.5) AND Creatinine >300 μmol/L (not 200) AND Grade III-IV encephalopathy (not Grade II). The pH <7.30 criterion has the strongest predictive value as it reflects severe metabolic acidosis from massive hepatocyte necrosis and lactate accumulation. INR >3.5 and bilirubin >300 are criteria for NON-paracetamol ALF, not paracetamol.